Peptide profile
Published Data as of
In a randomized trial in healthy adults, one CJC-1295 (with DAC) injection raised mean plasma growth hormone (GH) 2- to 10-fold. The rise lasted 6 days or more.1 In the same trial in people, insulin-like growth factor I (IGF-I) rose 1.5- to 3-fold for 9 to 11 days. The estimated half-life was 5.8 to 8.1 days.1 No serious adverse reactions were reported in that trial in people.1
In a randomized trial in healthy adults, a single CJC-1295 injection raised mean plasma growth hormone (GH) 2- to 10-fold for 6 days or more.1 Mean plasma IGF-I in that trial in people rose 1.5- to 3-fold for 9 to 11 days.1
The estimated half-life of CJC-1295 in the trial in people was 5.8 to 8.1 days.1 After multiple doses in the trial in people, mean IGF-I stayed above baseline for up to 28 days.1 No serious adverse reactions were reported in the trial in people.1
In a trial in healthy men, a single CJC-1295 injection raised overall mean GH by 46% one week later.5 Basal (trough) GH in that trial in people rose 7.5-fold one week later.5 IGF-I rose by 45% one week later in the same trial in people.5
The frequency and the magnitude of GH secretory pulses did not change in that trial in people.5 The IGF-I increases in people did not correlate with any measure of GH secretion.5
In a trial in healthy young men, an apolipoprotein A1 isoform spot in serum showed decreased intensity one week after a CJC-1295 injection.2 A transthyretin isoform spot in serum also dropped in intensity in that trial in people.2 Beta-hemoglobin in serum went up after treatment in the same trial in people.2
In the trial in young men, a C-terminal fragment of albumin in serum went up after treatment.2 A serum spot with an immunoglobulin fragment and another albumin fragment also went up in people. That spot had a linear relationship with IGF-1 levels.2
In a rat injected with CJC-1295, a Western blot showed the peptide on the serum albumin band from 15 min onward. That species stayed in circulation in rats beyond 24 h.6 In rats, CJC-1295 was present in plasma beyond 72 h.6
In rats given growth hormone-releasing hormone (GHRH) analogues into a vein, intact CJC-1295 was detected in plasma for at least 4 h.7 No expected metabolite of CJC-1295 was confirmed in plasma in rats.7 An immuno-PCR test confirmed CJC-1295 in blood samples in race horses after administration.3
The PepBank regulatory record lists CJC-1295 (with DAC) as not approved for any use, as of October 9, 2026.4 PepBank holds 10 studies with results for CJC-1295 (with DAC), listed in the CJC-1295 (with DAC) studies.8
CJC-1295 (with DAC) is in the list of peptides in PepBank, with 1 registered trial in its records.8 Its record holds 4 publications with findings in people. PepBank also has CJC-1295 (with DAC) compared with sermorelin.8
PepBank holds 4 publications with findings in people for CJC-1295 (with DAC), as of November 15, 2026.8 Those publications hold 20 findings in people.8 The records also hold 5 publications with findings in animals and 2 with laboratory findings in cells or tissue.8 The trial registry records in PepBank list 1 registered trial.8
The PepBank regulatory record lists CJC-1295 (with DAC) as not approved for any use, as of October 9, 2026. That status covers all places in the record.4 The trial registry records in PepBank list 1 registered trial that tests CJC-1295 (with DAC).8 PepBank holds 4 publications with findings in people for it.8
In a study of online forum threads by people discussing female use, users said they chose CJC-1295 for several reasons. These were weight loss, muscle enhancement, youthful skin, improved sleep and injury healing.9 In the same forum study of people, users raised concerns about dosage estimation, cycling and long-term consequences for women.9
In growth hormone-releasing hormone (GHRH) knockout mice, CJC-1295 given every 24 h gave normal body weight and normal body length.10 In mice lacking brain M3 muscarinic receptors, it restored normal pituitary size and normal serum GH and IGF-1 levels.11 In GHRH knockout mice, it also increased pituitary GH mRNA.10
In PepBank now:147 peptides, 6 blends and 13 other compounds97,577 study results from 17,383 studies8,473 clinical trialsUpdated